Some assets cannot be built on any timeline a budget can shorten. When that is true, the choice is no longer build, buy or licence. It is licence, or stay out. Bayer’s move into hybrid wheat this year is a clean example, and a useful test of any IP licensing strategy. The world’s largest seed company already runs its own hybrid wheat breeding programme and an established North American wheat franchise. It has still taken an exclusive licence to RAGT’s elite European wheat germplasm rather than breeding an equivalent or buying the French company outright. The stated ambition is a launch in the early 2030s and sales of up to a billion euros a year by the mid-2040s.

Why licence? Germplasm is the genetic base material a breeder starts from. Elite germplasm adapted to European growing conditions is the product of decades of selection, and no amount of capital compresses those decades. RAGT’s head of R&D said the deal reflects the value of genetics its breeders built up over that time. Bayer’s own wheat breeder put it plainly: they chose to license from RAGT because RAGT leads in Europe. For a company that wants to be selling seed by the early 2030s, the licence was the only route that arrived in time.

What a build, buy or licence decision looks like when time is the constraint

The durable lesson is that the licence is not the fallback option here. It is the strategy. Three disciplines follow, and none of them is specific to agriculture.

– Separate the inputs that are money-bound from the inputs that are time-bound. A plant, a sales force or a data centre can be bought. Decades of adapted breeding, a validated clinical dataset or a certified process cannot. Time-bound inputs are licensing decisions, and they need to be priced before the launch date is announced, because once the market knows your timetable the leverage sits with the licensor. As I argued in Capacity Is Not a Moat: What India’s Electrification Build-Out Means for Your IP Strategy, the in-licence is priced from the weakest seat once the capital is committed.

– If you are the one holding the time-bound asset, licensing beats selling. RAGT keeps its genetics, converts decades of breeding into a revenue line, and retains the option to license elsewhere by territory and crop class. That is the position I described in The Cash Behind the Compute: the asset that cannot be acquired on demand is the one everyone else must come to you for.

– Follow the value downstream. A hybrid bred several generations from licensed material blends RAGT genetics, Bayer breeding technology and new data. Much of that sits in know-how and breeding records protected by confidentiality and contract rather than by registered rights. So the agreement has to say who owns the new varieties, the improvements and the data, and who may use them outside the collaboration. Those clauses decide who is paid in the 2040s, and they are being written now.

Which inputs to your next product can only be licensed, and was that licence priced before the timetable went public?

Read the article: Bayer-RAGT IP Licensing Agreement Expands Hybrid Wheat Strategy, Pejman Javaheri, Juris Law Group.